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Abstract
Background:  Atrial fibrillation (AF) may arise out of anomalous impulse activity at atrial 
venous junctions. Triggered activity may be a source of abnormal impulse activity. Ranolazine is 
an anti-anginal agent, which inhibits normal and abnormal late Na+  channel current in the 
ventricle and peak Na+ channel current in the atrium. This produces an energy sparing effect and 
stabilizes cardiac membranes. Ranolazine is a potent inhibitor of triggered activity. The purpose 
of this report is to describe our initial experience with ranolazine used in patients with resistant 
AF.
Methods: Seven patients (4 males, 3 females, 67 ± 9 years) who developed recurrent AF within 
hours to a few days of restoring sinus rhythm despite AF ablation and /or failing one or more 
anti-arrhythmic agents were started on ranolazine (500-1000 mg/twice/day) after stopping all 
other anti-arrhythmic therapy. All but one patient had some form of associated structural heart 
disease.  
Results: Two patients received no apparent benefit from ranolazine developing recurrent AF 
within 2 days.  All other patients derived significant benefit. Four patients have experienced no 
recurrent AF. The other patient relapsed at 3 months and again at 6 months. The mean time in 
sinus rhythm to date, or to the first relapse, for the five responders was 27 ± 11 weeks.  No 
clinically   evident   pro-arrhythmic   episodes   occurred.  
Conclusion: Ranolazine was helpful in maintaining sinus rhythm in the majority of patients in 
which more established measures had failed. A controlled prospective trial is warranted to 
further investigate the efficacy of ranolazine in AF.
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Introduction
            In 1998, Haissaguerre et al demonstrated atrial fibrillation (AF) may originate and be 
perpetuated from ectopic activity originating at the junction of the left atrium and pulmonary 
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veins1. Subsequently, similar evidence has suggested that ectopic activity can also originate at 
the atrial junction of other thoracic veins; the vena cava and coronary sinus2,3. This localized 
source of AF forms the current basis for attempts to ablate AF by either surgical or catheter 
based techniques1-3. The electrophysiologic mechanisms responsible for the abnormal impulse 
activity have been the source of several investigations1-8. Recently it has been determined that 
triggered activity may be particularly important4-8.                                                         
               Ranolazine is an anti-anginal agent, which inhibits normal and abnormal late Na+ 
channel current in the ventricle and peak Na+ channel current in the atrium9-11. By this inhibition, 
it affects intracellular calcium handling producing an energy sparing effect9. Ranolazine has also 
been shown to be a potent inhibitor of after depolarizations produced by a number of 
mechanisms10,12,13. As such, it could prove to be particularly useful in the treatment of AF. 
Indeed, in the holter monitor data from the MERLIN trial, ranolazine was associated with a 
reduction in a number or several arrhythmias, including new episodes of AF14,15. In this case 
series we describe our initial experience using ranolazine as the sole anti-arrhythmic agent in 
patients in whom standard measures to control the AF had failed. This was a retrospective 
analyis of our results using ranolazine for atrial fibrillation, our institutional review board does 
not   require   approval   for   chart   review.                                                            
Methods
             Seven patients were started on ranolazine for the specific purpose of attempting to 
control AF after at least one anti-arrhythmic agent had failed. Each patient had been tried on at 
least   one   standard   anti-arrhythmic   agent   (dofetilide,   sotalol,   propafenone,   flecainide,   or 
amiodarone) at doses felt to be the maximum tolerated or clinically safe. Two patients had also 
undergone catheter-based ablation. Despite these measures, each of these patients had developed 
recurrent AF within hours to 3 days of restoring sinus rhythm either spontaneously or by 
electrical cardioversion. Six of 7 patients were highly aware of their AF with noticeable 
palpitations. One patient did not experience palpitations and was unaware of his AF; presenting 
instead with congestive heart failure and severe left ventricular dysfunction. The AF was 
classified as "persistent" if it failed to self convert and required electrical cardioversion to restore 
sinus rhythm. AF was classified as paroxysmal if the AF alternated with sinus rhythm via 
spontaneous   relapses   and   self-conversion.                                                    
            The age, sex, left ventricular ejection fraction (%), left atrial diameter (mm) and volume 
index (ml/m²) by echocardiography, number of anti-arrhythmic agents tried prior to ranolazine 
(not including beta blockers or calcium channel blockers), and associated structural heart 
condition and other health conditions were determined for each patient. The nature of the AF 
problem   (paroxysmal   or   persistent)   was   also   determined   for   each   patient.  
            Each patient was advised that this was an "off label" use of ranolazine and that the 
benefits and risks were unknown. Ranolazine was started only after stopping other anti-
arrhythmic therapy. Ranolazine was started at 500 mg twice a day and if tolerated generally 
increased within 2 to 4 days to 1000 mg twice a day in patients with a weight exceeding 70 kg. If 
the patient was on amiodarone immediately prior to ranolazine, amiodarone was discontinued at 
least 4 weeks before ranolazine was begun. All other anti-arrhythmic agents were discontinued 
at least 3 half lifes (if in hospital with ECG monitoring, 4 patients) or 5 half lifes if stated in the 
unmonitored or outpatient setting (3 patients). Patients were not hospitalized for ranolazine 
initiation. Those in the hospital at the time it was started had been admitted for standard anti-
arrhythmic therapy, but failed therapy within a day of cardioversion. Four patients were in AF 
when ranolazine was started and were cardioverted to sinus rhythm within a few days. Three 
patients had incessant paroxysmal AF and were in sinus rhythm when started on ranolazine. The 
duration in weeks for all patients who remained in sinus rhythm for at  least  1  week  after 
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restoring sinus rhythm was determined and the mean   ± 1 standard deviation for the group 
calculated. The specific details for anybody relapsing into AF was noted and reported.          
Results
            Table 1 describes the clinical characteristics of the patients in which ranolazine was used 
to treat AF. Note the wide spectrum of associated medical conditions and structural heart 
disease. Six of the 7 patients had left atrial enlargement as measured by an elevated left atrial 
volume index exceeding 26 ml/m².                                                                                 
Table 1.  Clinical Characteristics of AF patients
AF: atrial fibrillation, CAD: coronary artery disease, COPD: chronic obstructive pulmonary disease, EF: ejection 
fraction, LAD: left atrial diameter (mm), LAE: left atrial enlargement, LAVI: left atrial volume index (ml/m²), 
LVH: left ventricular hypertrophy, OSA: obstructive sleep apnea, RHD: rheumatic heart disease.
            Table 2 details the clinical effect of ranolazine on AF as well as the dose employed. 
Ranolazine was effective in maintaining sinus rhythm in 5 patients. Four of these five have had 
no recurrent AF. One of the 5 patients (#1) did develop recurrent AF. This patient had a 12-year 
history of lone AF (normal left atrial size initially). AF was initially infrequent and controlled 
with beta-blockers and occasional cardioversion. As left atrial size increased over time, the AF 
became increasingly problematic. Amiodarone, dofetilide, sotalol, and flecainide had each 
failed. The patient under went catheter-based ablation at an outside institution. After a brief 
period of benefit, recurrent AF led to 3 repeat cardioversions whereby sinus rhythm would last 
only 1 to 3 days. Another ablation was contemplated. Instead ranolazine was started as an 
outpatient and the patient electrically cardioverted 3 days later. Normal sinus rhythm persisted 
for 12 weeks before recurrent AF occurred. After electrical conversion on ranolazine, sinus 
rhythm was again maintained for another 12 weeks before a second relapse occurred. Following 
this second relapse, ranolazine was abandoned as a therapeutic option and the patient now 
remains in chronic AF with possible plans for a second attempt at radio frequency ablation. 
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Table 2.  AF Characteristics and Ranolazine effects
A: amiodarone, D: dofetilide, S: sotalol, F: flecainide, NSR: normal sinus rhythm, PAF: paroxysmal atrial 
fibrillation
               Two patients had no apparent benefit from ranolazine. Both patients had incessant 
paroxysmal AF with several episodes of AF each day. Both failed numerous anti-arrhythmic 
agents without any apparent clinical benefit. Both continued to have incessant paroxysmal AF 
despite   ranolazine   at   2000   mg/day.                                                                    
               All other patients remain in sinus rhythm without relapse despite having had very 
challenging AF. The mean time in sinus rhythm to date, or to the first relapse, for the five 
responders was 27 ± 11 weeks.   No clinically evident pro-arrhythmic events were noted in any 
patient. Nobody discontinued ranolazine because of side effects.                                   
Discussion
            Maintaining sinus rhythm in patients with AF can be particularly challenging. Despite 
anti-arrhythmic therapy, AF continued to be highly problematic in each of our patients. Each 
patient with paroxysmal AF had daily episodes of AF.  Each patient with persistent AF had 
undergone numerous cardioversions with rapid relapse to AF.  Since each patient had highly 
symptomatic AF (6 patients) or experienced a severe deterioration of left ventricular function as 
a consequence of their AF (1 patient), we pursued an aggressive approach to AF in these 
patients.
            We found ranolazine to be effective in suppressing AF in the majority of patients with 
persistent AF stemming from a variety of causes (Table 2). Most patients with persistent AF 
remain in sinus rhythm as of this writing (Table 2). Prior to ranolazine each of these patients had 
relapsed to AF within 3 days of last cardioversion. However, like all pharmacological agents, 
ranolazine did not prevent all AF. It appeared to have little effect in 2 of the 3 patients with 
frequent   paroxysmal   AF.                                                                              
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            The possible utility of ranolazine to treat clinical arrhythmias is only now beginning to 
emerge. In 6560 patients surviving an acute coronary syndrome, the MERLIN investigators 
noted that ranolazine was associated with a significant reduction in a variety of asymptomatic 
atrial and ventricular arrhythmias as recorded on prolonged holter monitoring14,15. Importantly, 
in extensive clinical studies to date, the pro-arrhythmic potential of ranolazine appears to be very 
low14-16.   None   of   the   patients   in   our   series   had   a   symptomatic   pro-arrhythmic   event.
               The mechanism for the anti-arrhythmic effects observed with ranolazine is likely 
complex. Ranolazine slightly prolongs the action potential duration by inhibiting the slow 
sodium current and the slow component of the delayed rectifying potassium current12.  In atrial 
tissue, the inhibition of the peak sodium current prolongs repolarization and induces post 
repolarization   refractoriness11.   This   effect   could   potentially   block   re-entrant   pathways. 
However, it is its effect on triggered activity, which appear most powerful. In tissue bath 
preparations, ranolazine reduces the repetitive extra systoles produced by triggered activity from 
a number of different causes10,12,13. Ranolazine affectively prevents or attenuates AF in canine 
models   of   this   arrhythmia11.                                                                            
Limitations
            The small number of patients in our report makes it essential that these observations be 
confirmed. Additionally, this was a real life experience with ranolazine. Like all real life clinical 
decision making regarding anti-arrhythmic therapy, we gauged the effectiveness of ranolazine 
based on the past history of very resistant AF and the significant change in that pattern after 
institution of ranolazine. Finally, we used ranolazine as a last resort measure only. It is possible 
that these criteria artificially selected a group of patients more likely to respond to ranolazine. 
The use of ranolazine for less resistant AF remains uninvestigated.                                           
In   summary                                                                                      
            Our investigation confirms the anti-arrhythmic properties of ranolazine and is the first 
report on the specific use of ranolazine to treat symptomatic AF.  We found ranolazine to be 
effective in suppressing AF in the majority of patients with resistant AF stemming from a variety 
of causes. Given the lack of known pro-arrhythmic potential and end organ toxicity, as well as 
the ability to initiate therapy in an outpatient setting, the potential implications of the present 
observations are obvious. If the effectiveness of ranolazine is confirmed in larger controlled trial, 
this agent could emerge as the drug of first choice for AF rather than the manner we employed it. 
The small number of patients demands us to be cautious before extrapolating to the larger 
clinical setting and highlights the need for larger controlled studies to investigate the possible 
utility of ranolazine to treat this difficult and pervasive problem. 
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